Want to join the conversation?
$BIIB 2Q15 Q&A: Schoenebaum of Evercore asked about TECFIDERA volume in the US and M&A. Paul said there is very modest patient growth. BIIB is assuming limited patient growth on a sequential basis in US. George added that on M&A, BIIB is not engaged in M&A for any short term stock performance but want to add additional compounds to its portfolio.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?